Clinical trials: Adjuvant Immunotherapy
Melanoma
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma.
- Trial name
- CheckMate 238 (NCT02388906)
- Testing
- Ipilimumab, Nivolumab
- Where
- 136 sites in United States, Argentina and 23 more
- Volunteers
- 906 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
The purpose of this study is to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.
- Trial name
- RELATIVITY-098 (NCT05002569)
- Testing
- Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination
- Where
- 184 sites in United States, Argentina and 23 more
- Volunteers
- 1,093 people
- Sponsor
- Bristol-Myers Squibb
Melanoma, Squamous Cell Carcinoma of the Head and Neck
Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)
The purpose of this study is to test the safety of a course of injections containing Poly-ICLC in patients with advanced solid tumors that can be easily and safely reached with a needle.
- Conditions
- Melanoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma of the Skin, Sarcoma of the Skin
- Trial name
- Hiltonol (NCT01984892)
- Testing
- Poly-ICLC
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Nina Bhardwaj
Melanoma
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
The purpose of this study is to determine the effectiveness of nivolumab adjuvant immunotherapy compared to placebo in adults and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease…
- Trial name
- CheckMate76K (NCT04099251)
- Testing
- Nivolumab
- Where
- 130 sites in United States, Australia and 18 more
- Volunteers
- 790 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma, Lymphocytic Leukemia, Chronic
Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant
The purpose of this study is to determine whether a reduced intensity conditioning regimen for stem cell transplant with donor cells will allow the donor cells to be effective without causing health problems.
- Conditions
- Multiple Myeloma, Lymphocytic Leukemia, Chronic, Lymphoma, Low-Grade
- Trial name
- NCT00143845
- Testing
- Reduced intensity conditioning, Rapid immunosuppressive taper, Prophylactic donor leukocyte infusions
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Michigan Rogel Cancer Center
Melanoma, Melanoma Stage III
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
The main purpose of this study is to compare the efficacy of bempegaldesleukin plus nivolumab versus nivolumab in patients with completely resected Stage IIIA/B/C/D, or Stage IV cutaneous melanoma who are at high risk for…
- Conditions
- Melanoma, Melanoma Stage III, Melanoma Stage IV, Melanoma (Skin)
- Trial name
- PIVOT-12 (NCT04410445)
- Testing
- Bempegaldesleukin, Nivolumab
- Where
- 212 sites in United States, Australia and 15 more
- Volunteers
- 765 people
- Sponsor
- Nektar Therapeutics
Melanoma
An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma
The purpose of this study is to determine whether an investigational immunotherapy Nivolumab, when combined with Ipilimumab, is more effective than Nivolumab by itself, in delaying the return of cancer in patients who have had a…
- Trial name
- CheckMate 915 (NCT03068455)
- Testing
- nivolumab, ipilimumab
- Where
- 124 sites in United States, Australia and 17 more
- Volunteers
- 1,844 people
- Sponsor
- Bristol-Myers Squibb